Eli Lilly Price Target Raised to $880 by Rothschild & Co Redburn

Analysts cite strong performance and growth potential for the pharmaceutical giant.

Apr. 11, 2026 at 12:20pm

Got story updates? Submit your updates here. ›

An extreme close-up of complex pharmaceutical manufacturing equipment and machinery, conveying the industrial scale and technical sophistication behind Eli Lilly's drug development and production.Eli Lilly's robust production capabilities and technological prowess power its position as a dominant force in the global pharmaceutical industry.Indianapolis Today

Eli Lilly and Company (NYSE:LLY) had its price target increased from $875 to $880 by research firm Rothschild & Co Redburn. The firm maintained a neutral rating on the stock, citing the company's continued strong performance and growth outlook in the pharmaceutical industry.

Why it matters

Eli Lilly is one of the world's largest and most influential pharmaceutical companies, with a diverse portfolio of blockbuster drugs and a robust pipeline of new treatments. Analyst price target changes can significantly impact investor sentiment and trading activity around the stock.

The details

In its report, Rothschild & Co Redburn cited Eli Lilly's solid financial results and promising drug development progress as the key factors behind the price target increase. The firm noted that Eli Lilly has outperformed many of its peers in recent quarters, driven by strong sales of existing medications as well as the successful launch of new products.

  • Rothschild & Co Redburn released its updated report on Eli Lilly on Friday, April 11, 2026.

The players

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. Eli Lilly researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide.

Rothschild & Co Redburn

A prominent global investment banking and securities firm that provides research coverage and analysis on Eli Lilly and other major pharmaceutical companies.

Got photos? Submit your photos here. ›

The takeaway

Eli Lilly's strong financial performance and promising drug pipeline have led analysts to raise their price targets, signaling continued confidence in the company's growth potential within the competitive pharmaceutical industry.